1. Home
  2. ALLO vs LPA Comparison

ALLO vs LPA Comparison

Compare ALLO & LPA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALLO
  • LPA
  • Stock Information
  • Founded
  • ALLO 2017
  • LPA 2013
  • Country
  • ALLO United States
  • LPA United States
  • Employees
  • ALLO N/A
  • LPA N/A
  • Industry
  • ALLO Biotechnology: Biological Products (No Diagnostic Substances)
  • LPA
  • Sector
  • ALLO Health Care
  • LPA
  • Exchange
  • ALLO Nasdaq
  • LPA Nasdaq
  • Market Cap
  • ALLO 338.9M
  • LPA 310.7M
  • IPO Year
  • ALLO 2018
  • LPA N/A
  • Fundamental
  • Price
  • ALLO $1.55
  • LPA $6.47
  • Analyst Decision
  • ALLO Strong Buy
  • LPA
  • Analyst Count
  • ALLO 10
  • LPA 0
  • Target Price
  • ALLO $9.66
  • LPA N/A
  • AVG Volume (30 Days)
  • ALLO 2.6M
  • LPA 18.8K
  • Earning Date
  • ALLO 05-12-2025
  • LPA 05-14-2025
  • Dividend Yield
  • ALLO N/A
  • LPA N/A
  • EPS Growth
  • ALLO N/A
  • LPA N/A
  • EPS
  • ALLO N/A
  • LPA N/A
  • Revenue
  • ALLO $22,000.00
  • LPA $43,862,372.00
  • Revenue This Year
  • ALLO N/A
  • LPA N/A
  • Revenue Next Year
  • ALLO $9.07
  • LPA N/A
  • P/E Ratio
  • ALLO N/A
  • LPA N/A
  • Revenue Growth
  • ALLO N/A
  • LPA 11.22
  • 52 Week Low
  • ALLO $1.23
  • LPA $6.00
  • 52 Week High
  • ALLO $3.78
  • LPA $525.00
  • Technical
  • Relative Strength Index (RSI)
  • ALLO 49.84
  • LPA N/A
  • Support Level
  • ALLO $1.38
  • LPA N/A
  • Resistance Level
  • ALLO $1.75
  • LPA N/A
  • Average True Range (ATR)
  • ALLO 0.13
  • LPA 0.00
  • MACD
  • ALLO 0.04
  • LPA 0.00
  • Stochastic Oscillator
  • ALLO 61.54
  • LPA 0.00

About ALLO Allogene Therapeutics Inc.

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.

About LPA Logistic Properties of the Americas

Logistic Properties of the Americas is a fully-integrated, internally managed real estate company that develops, owns and manages a diversified portfolio of warehouse logistics assets in Central America and the South America. It focuses on modern Class A logistics real estate in high growth and high barrier-to-entry markets that are undersupplied and have low penetration rates.

Share on Social Networks: